Articles tagged with “antibody-drug-conjugates”

Pfizer-Innovent $10.5B Deal & China Licensing Playbook

Examine the $10.5B Pfizer-Innovent collaboration. This analysis covers their 12-drug ADC oncology portfolio and the China cross-border licensing playbook.

35 min read

5/13/2026

pfizer innovent deal oncology licensing antibody drug conjugates cross-border licensing cancer drug development multispecific antibodies pharma partnerships china biotech

Gilead-Tubulis $5B Acquisition: ADC Oncology Strategy

Analyze Gilead's $5 billion acquisition of Tubulis, examining antibody-drug conjugate (ADC) oncology strategy, market trends, and new clinical platforms.

40 min read

4/17/2026

antibody-drug conjugates gilead sciences tubulis oncology strategy pharma acquisitions targeted cancer therapy adc market trends